This site is intended for health professionals only
Monday 27 May 2019
Share |

Topic: Remsima

December 12, 2016
The European Crohn's and Colitis Organisation's latest position paper supports switching from the originator to a biosimilar in patients with IBD.

Celltrion Healthcare welcomes the publication of the latest position paper from the European Crohn’s and Colitis Organisation (ECCO) on the use of biosimilars for inflammatory bowel disease (IBD), which supports switching from reference infliximab to biosimilar infliximab.1

 

 The ECCO statement covers several aspects related to biosimilars and the key positions are:1

January 11, 2016
In a study of 397 patients with ulcerative colitis and Crohn’s disease, 93 patients (23%) were switched to a biosimilar infliximab from the reference infliximab, representing the largest group of switch patients studied to date in inflammatory bowel diseases
  • In a study of 397 patients with ulcerative colitis and Crohn’s disease, 93 patients (23%) were switched to a biosimilar infliximab from the reference infliximab, representing the largest group of switch patients studied to date in inflammatory bowel diseases (IBD)1
     
March 3, 2015
• The European Medicines Agency has determined that Remsima, a biosimilar, is comparable to the reference product Remicade® in terms of safety, efficacy and quality across all approved indications • Remsima is expected to cost less than the reference product; these savings could allow more patients with inflammatory autoimmune diseases to access monoclonal antibody therapy • Biosimilar monoclonal antibodies are expected to save European healthcare systems between €1.8 and €20.4 billion between 2007 and 2020 (1)

•    The European Medicines Agency has determined that Remsima, a biosimilar, is comparable to the reference product Remicade® in terms of safety, efficacy and quality across all approved indications
•    Remsima is expected to cost less than the reference product; these savings could allow more patients with inflammatory autoimmune diseases to access monoclonal antibody therapy

February 20, 2015
Celltrion Healthcare has announced data demonstrating the healthcare savings achievable by using Remsima™ (CT-P13), a biosimilar monoclonal antibody infliximab, to treat patients with Crohn’s disease (CD) in France, Italy and the UK. (1)

Celltrion Healthcare has announced data demonstrating the healthcare savings achievable by using Remsima™ (CT-P13), a biosimilar monoclonal antibody infliximab, to treat patients with Crohn’s disease (CD) in France, Italy and the UK. (1)

 

 

August 15, 2014
Mundipharma International Corporation Limited has announced that it has secured a distribution licence from Celltrion Healthcare Hungary Kft for Remsima (infliximab).

Mundipharma International Corporation Limited has announced that it has secured a distribution licence from Celltrion Healthcare Hungary Kft for RemsimaTM (infliximab).

Following expiry of the relevant patents and Supplementary Protection Certificate’s, Mundipharma and its independent associated companies will have exclusive rights to market Remsima in the UK, Germany, Italy, Belgium, Luxembourg and the Netherlands.

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine